United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules are contraindicated in patients with: • active pathological bleeding [see warnings and precautions ( 5.2) and adverse reactions ( 6.1)] • history of a seri

United States - English - NLM (National Library of Medicine)

american health packaging - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules are contraindicated in patients with: - active pathological bleeding [see warnings and precautions (5.2) and adverse reactions (6.1)] - history of a serious hypersensitivity

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - valganciclovir - film-coated tablet - valganciclovir 450 mg - antivirals for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - valganciclovir hydrochloride - film coated tablet - 450 milligram - valganciclovir

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - valganciclovir hydrochloride - oral tablet - 450mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - valganciclovir hydrochloride - oral tablet - 450mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - valganciclovir hydrochloride - oral tablet - 450mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - valganciclovir hydrochloride - oral tablet - 450mg

Israel - English - Ministry of Health

teva israel ltd - dabigatran etexilate as mesylate - capsules - dabigatran etexilate as mesylate 150 mg - dabigatran etexilate - prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.